DGAP-News: QUANTRO Therapeutics GmbH
/ Key word(s): Personnel
30.04.2021 / 10:00
The issuer is solely responsible for the content of this announcement.
QUANTRO Therapeutics appoints Dr. Elmar Maier as Independent Board Chairman
Vienna, Austria, 30 April 2021: QUANTRO Therapeutics GmbH today announced the appointment of Dr. Elmar Maier as Independent Chairman of its Board.
Elmar has a long-standing track record as a seasoned dealmaker in the life science industry. Over the last 26 years, he has co-founded several biotech companies (including GPC Biotech AG and iOmx Therapeutics AG) and held C-level positions on multiple management teams in private and public biotech companies. He has helped biotech companies to establish large R&D collaborations generating several hundred million dollars cash up-front, raise significant equity funding and execute M&A transactions. Elmar holds a degree in chemistry and obtained his Ph.D. from the University of Konstanz, Germany. He was a scientist at the ICRF Laboratories in London and Department Head at the Max Planck Institute for Molecular Genetics in Berlin. In addition to QUANTRO, he has served as a Board member for several biotech companies.
Dr. Dieter Nachtigall, Chief Executive Officer of QUANTRO, said: “We are delighted to have Elmar join the QUANTRO Board. He is a highly successful and respected leader in the industry, and we will benefit greatly from his strategic advice and strong business development expertise. Additionally, his knowledge of effectively building and growing drug discovery companies will be invaluable as we move QUANTRO forward. Throughout his career, Elmar has shown strong leadership capabilities and an innovative spirit, making him an excellent fit for QUANTRO. I look forward to working closely with him and the other Board members as we carry out our mission of identifying and developing new anti-cancer agents with breakthrough potential.”
Dr. Elmar Maier, Chairman of the Board of QUANTRO, added: “Transcription factors are key regulators of gene expression and represent a unique class of drug targets, but direct modulation by small molecules until now has been notoriously difficult. I am very excited about QUANTRO’s proprietary drug discovery platform combining genome engineering, next-gen cell-based compound screening, metabolic RNA sequencing and bioinformatics to rapidly identify novel drug candidates targeting such central transcriptional activities. I look forward to working with the QUANTRO team to build the company through a combination of an internal drug development pipeline and partnerships with leading pharmaceutical companies.”
About QUANTRO Therapeutics GmbH
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.